Intersect Capital’s NeuroOne Medical Technologies NMTC Stock Holding History

Intersect Capital’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$41K	Hold	8,333	–	–	0.01%	343
2022 Q1	$55K	Hold	8,333	–	–	0.01%	435
2021 Q4	$97K	Hold	8,333	–	–	0.02%	424
2021 Q3	$198K	Buy	+8,333	New	+$239K	0.03%	383

Other funds holding NMTC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DWM

Drive Wealth Management Lehi, Utah $561M AUM 33.14% 1-Year Est. Return

KCIA

Kingsbury Capital Investment Advisors Wilmette, Illinois $65.6M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Intersect Capital's NMTC Position: Q2 2022 in Review

Intersect Capital held its NeuroOne Medical Technologies (NMTC) position steady in Q2 2022 at 8,333 shares worth $41K. The position accounts for 0.01% of the portfolio, ranked #343.

Intersect Capital first reported a position in NMTC in Q3 2021 and has held it in 4 quarters since. The position peaked at $198K in Q3 2021. 10 funds tracked by Wall St. Rank hold NMTC as of Q2 2022.

Intersect Capital held 8,333 shares of NeuroOne Medical Technologies worth $41K as of Q2 2022.
Intersect Capital left its NeuroOne Medical Technologies share count unchanged in Q2 2022.
NeuroOne Medical Technologies made up 0.01% of Intersect Capital's portfolio in Q2 2022, its #343 holding.
Intersect Capital first reported a position in NeuroOne Medical Technologies in Q3 2021 and has held it in 4 quarters since.
Intersect Capital's NeuroOne Medical Technologies position peaked at $198K in Q3 2021.
10 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2022.

Based on Intersect Capital's 13F filing for Q2 2022, filed 2 Sep 2022.